ARTICLE | Product Development
COVID-19 roundup: Amgen taps Adaptive as its antibody therapeutic partner; plus Alnylam-Vir’s siRNA targets, Ansun’s data and more
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
April 3, 2020 12:36 AM UTC
Updated on Apr 3, 2020 at 1:00 AM UTC
Amgen entered the race to develop an antibody-based COVID-19 therapy Thursday, partnering with Adaptive Biotechnologies to screen for neutralizing mAbs. The day also saw Alnylam and Vir name the first targets from their siRNA partnership and data for a recombinant sialidase therapy.
Neutralizing mAbs against SARS-CoV-2 have arisen as a leading approach among companies designing preclinical therapies for COVID-19. At least 20 groups have disclosed mAb programs (see “COVID-19 Therapies and Vaccines: Preclinical”)...